“Breaking into neurology is a major priority. Society is currently bearing a heavy burden from neurological diseases.”
As cell and gene therapies move from concept to clinic, the complexity of their supply chains demands new levels of coordination, innovation, and adaptability. In this interview, Abi Pinchbeck, Commissioning Editor, Cell & Gene Therapy Insights, speaks with Phillip Ramsey, Chief Technical Officer, Sangamo Therapeutics, who shares insights from Sangamo’s evolving strategy, highlighting the critical role of technology, collaboration, and platform development in building a more resilient and patient-centric delivery model.
